New study
in islet transplantation
first patient transplanted!
anti CD40L antibody
new immunosuppression
Allotransplantation for patients with T1DM
OPEN ENROLLMENT
A pilot study assessing the safety, tolerability and efficacy of using monoclonal anti- CD40L antibody (Tegoprubart) to achieve calcineurin inhibitor-free immunosupression regimen in patients undergoing islet transplantation
Funded by JDRF/ The Cure Alliance/ Eledon
To Our Dear Patients,
I am writing to let you know about an opportunity to participate in a research study designed for patients with "brittle" form of Type 1 Diabetes.
This study is being conducted by myself, Dr. John Fung with help of Dr.. Piotr Witkowski at the University of Chicago. This research study will assess the safety, tolerability and efficacy of new medication (Tegoprubart, Eledon) used to protect islets from immunologic rejection after transplantation.
You may be eligible for this study if:
-
you are between the ages of 18-65,
-
A1c 7.0- 9.5
-
have been diagnosed with Type 1 Diabetes for longer than 5 years,
-
suffer from sudden and unpredictable drops of blood glucose leading to confusion or passing out despite the best medical treatment of insulin under the guidance of an experienced diabetologist.
If you are interested in learning more about the study, please contact our Research Manager Lindsay Basto, RN, MSN, Lindsay.Basto@uchospitals.edu or call 773-702-2504 for additional information.
It is important to know that this letter is not to tell you to join the study.
It is your decision, and your participation is voluntary.
Whether you show interest, and participate in the study or not, it will have no effect on your treatment with your doctors.
Thank you for your interest and consideration,
John Fung MD PhD
More information about the study can be found on ClinicalTrials.Gov and in the recent press release from our sponsors: